Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study Comparing Duloxetine and Placebo in the Treatment of Fibromyalgia

Phase 4

Completed

Conditions: Fibromyalgia

Interventions: Drug: duloxetine hydrochloride
Drug: placebo

First Posted Date: 2008-05-07

Last Posted Date: 2010-06-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 530

Registration Number: NCT00673452

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico

Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis

Phase 3

Completed

Conditions: Osteoporosis, Postmenopausal

Interventions: Drug: Raloxifene HCL
Drug: Placebo

First Posted Date: 2008-05-01

Last Posted Date: 2008-05-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 7705

Registration Number: NCT00670319

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London Bridge, United Kingdom

Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis

Phase 3

Completed

Conditions: Osteoporosis, Postmenopausal

Interventions: Drug: Placebo
Drug: teriparatide
Drug: Calcium Supplement
Drug: Vitamin D Supplement

First Posted Date: 2008-05-01

Last Posted Date: 2008-05-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1637

Registration Number: NCT00670501

Locations: 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uppsala, Sweden

A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma

Phase 2

Completed

Conditions: Synovial Sarcoma
Rhabdomyosarcoma
Leiomyosarcoma
Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET)
Adipocytic Sarcoma

Interventions: Biological: IMC-A12 (cixutumumab)

First Posted Date: 2008-04-29

Last Posted Date: 2018-07-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 113

Registration Number: NCT00668148

Locations: 🇪🇸
ImClone Investigational Site, Barcelona, Spain

A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes Patients

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin Glargine
Drug: Insulin Lispro Protamine Suspension (ILPS)
Drug: Insulin Lispro

First Posted Date: 2008-04-25

Last Posted Date: 2011-05-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 374

Registration Number: NCT00666718

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Bromwich, West Midlands, United Kingdom

A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression

Phase 4

Completed

Conditions: Depression

Interventions: Drug: duloxetine
Drug: citalopram
Drug: fluoxetine
Drug: sertraline
Drug: paroxetine

First Posted Date: 2008-04-25

Last Posted Date: 2010-06-15

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 750

Registration Number: NCT00666757

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brown Deer, Wisconsin, United States

Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin Lispro Premix (mid-mixture and low-mixture)
Drug: Insulin Glargine

First Posted Date: 2008-04-23

Last Posted Date: 2011-12-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 344

Registration Number: NCT00664534

Locations: 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Konya, Turkey

A Long-term Study for the Treatment of Painful Diabetic Neuropathy

Phase 3

Completed

Conditions: Diabetic Neuropathies

Interventions: Drug: Duloxetine hydrochloride

First Posted Date: 2008-03-24

Last Posted Date: 2011-03-31

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 258

Registration Number: NCT00641719

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toyama, Japan

A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: docetaxel
Drug: LY2181308 sodium
Drug: Prednisone

First Posted Date: 2008-03-24

Last Posted Date: 2019-04-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 154

Registration Number: NCT00642018

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pamplona, Spain

Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)

Phase 2

Completed

Conditions: Diabetes Mellitus
Coronary Artery Disease

Interventions: Drug: prasugrel
Drug: Clopidogrel

First Posted Date: 2008-03-24

Last Posted Date: 2010-02-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 35

Registration Number: NCT00642174

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy